Last reviewed · How we verify

NCT05474703

Evaluation of the Effects of Levonorgestrel-releasing Intrauterine Device and Dydrogestreone on Quality of Life and Sexual Life in Patients With Abnormal Uterine Bleeding.

Status unknown Last updated 29 July 2022
What this trial tests

trial testing SF-36 Scores in Abnormal Uterine Bleeding in 171 participants. Status unknown.

Timeline
20 February 2022
Primary endpoint
24 July 2022
10 August 2022

Quick facts

Lead sponsorKanuni Sultan Suleyman Training and Research Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment171
Start date20 February 2022
Primary completion24 July 2022
Estimated completion10 August 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kanuni Sultan Suleyman Training and Research Hospital

Who can join

Adults 18 to 45, female only, with Abnormal Uterine Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was retrospectively collected from patients who were diagnosed with abnormal uterine bleeding and received oral dydrogesterone therapy for at least six months or who were administered an intrauterine device containing levonorgestrel at least six months ago, and prospectively Short form 36 (P-36); It covers the comparison of the Quality of Life Scale and the Female Sexual Function Scale (FSFI) by asking over the phone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Abnormal Uterine Bleeding

Currently open trials in the same condition.

Other Kanuni Sultan Suleyman Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05474703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing